Investor profile
Third Rock Ventures
VC
See how your deck fits this investor's thesis, stage, and ticket size.
Analyse your fitInvestment thesis
Third Rock Ventures operates on a distinctive 'Discover-Launch-Build-Transform' methodology, believing that breakthrough science merged with operational rigor creates transformational opportunities in life sciences. Rather than investing in fully-formed companies, the firm collaborates with world-class scientific founders and expert advisors to actively shape company formation from inception — defining structure, vision, strategy, and leadership before launch. Third Rock focuses on identifying emerging fields at the intersection of science and unmet medical need, with a priority on areas such as oncology, rare genetic disorders, cardiovascular disease, neuropsychiatry, autoimmune diseases, and gene/cell therapy. The firm's hands-on approach spans drug discovery, clinical strategy, business operations, and talent acquisition, with partners typically taking board seats and playing active governance roles throughout the company lifecycle.
Notable quotes
“We believe in a mentality of Third Rock forever.”
“One of Third Rock's founding principles is the importance of collaboration and a philosophy of group genius. With this as a core value, we employ an evergreen approach to bringing together the best and brightest across the industry.”
“Our founding vision was based on an operating model rooted in a team-oriented approach, cultivated through group genius.”
Team
Recent investments
| Company | Round | Size | Date |
|---|---|---|---|
| Syremis Therapeutics | Series A | $165m | 2025-12-18 |
| Azalea Therapeutics | Series A | $82m | 2025-11-01 |
| ARTBIO | Series B | $132m | 2025-07-01 |
| Trace Neuroscience | Series A | $101m | 2024-11-12 |
| Candid Therapeutics | Series A | $370m | 2024-09-09 |
| Marea Therapeutics | Series A | $190m | 2024-01-01 |
| Blueprint Medicines | Series A | — | 2011-01-01 |
| Sage Therapeutics | Series A | — | 2011-01-01 |
| Editas Medicine | Series A | — | 2013-01-01 |
| Agios Pharmaceuticals | Series A | — | 2010-01-01 |
Frequent co-investors
Fit check
Is Third Rock Ventures a match for your startup?
Upload your deck and get an instant AI-powered fit analysis — see exactly how your startup aligns with this investor's thesis, stage focus, and ticket size.
Analyse your fit